A Study to Assess the Response Rate of PROCRIT (Epoetin Alfa) Given at a Dose of 40,000 Units Once a Week to Cancer Patients With Anemia Who Are Not Receiving Chemotherapy.

NCT00350090 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

98

Enrollment

INDUSTRY

Sponsor class

Stopped This study was stopped early due to slow enrollment.

Conditions

Anemia
Neoplasms

Interventions

DRUG: Epoetin Alfa

Sponsor

Ortho Biotech Products, L.P.